Enrolling by invitationNCT06363760
A Long-Term Follow-Up Study of Participants With Sickle Cell Disease or Transfusion Dependent β-Thalassemia Who Received EDIT-301
Studying Sickle cell disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Editas Medicine, Inc.
- Intervention
- Safety and efficacy assessments(other)
- Enrollment
- 54 enrolled
- Eligibility
- 12-50 years · All sexes
- Timeline
- 2024 – 2040
Study locations (18)
- UCSF Benioff Children's Hospital, Oakland, California, United States
- Children's Hospital Colorado, Aurora, Colorado, United States
- Smilow Cancer Hospital, New Haven, Connecticut, United States
- Johns Hopkins All Children's Hospital, St. Petersburg, Florida, United States
- Children's Healthcare of Atlanta, Atlanta, Georgia, United States
- University of Minnesota, Minneapolis, Minnesota, United States
- Columbia University Medical Center - Department of Pediatrics, New York, New York, United States
- Columbia University Medical Center, New York, New York, United States
- Atrium Health, Charlotte, North Carolina, United States
- Cleveland Clinic, Cleveland, Ohio, United States
- Nationwide Children's Hospital, Columbus, Ohio, United States
- Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
- Medical University of South Carolina, Charleston, South Carolina, United States
- Tristar Medical Group Children's Specialists/Sarah Cannon Center for Blood Cancers, Nashville, Tennessee, United States
- Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States
- +3 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06363760 on ClinicalTrials.govOther trials for Sickle cell disease
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE4NCT06979492Prophylactic Transfusion In Pregnant in Women With Sickle Cell DiseaseEmory University
- RECRUITINGNCT07392216Functional Ovarian Reserve in Sickle Cell DiseaseSt. Jude Children's Research Hospital
- RECRUITINGNANCT07246265Morphine Clearance and Glomerular Filtration in Sickle Cell Patients in Crisis in Intensive CareUniversity Hospital, Tours
- ENROLLING BY INVITATIONPHASE2NCT07401823Open-Label Extension Study to Pioneer Study 6058-SCD-101Fulcrum Therapeutics
- RECRUITINGPHASE1, PHASE2NCT07432867Efficacy Safety Study of Gene Therapy for Sickle Cell DiseaseSCD Using Autologous CD34+ Cells Transduced ex Vivo, Carrying a Corrected Globin Gene and a Silencing RNA.Assistance Publique - Hôpitaux de Paris
- RECRUITINGNANCT07222475Writing Relaxing Beats in Adolescents Who Have Sickle Cell DiseaseMayo Clinic
- RECRUITINGPHASE2NCT07224360Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD)CSL Behring
- RECRUITINGPHASE3NCT07247188Study of a Single Dose of a 21-valent Pneumococcal Conjugate Vaccine in Children and Adolescents With Sickle Cell DiseaseSanofi